| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Needham analyst Mike Matson upgrades TransMedics Group (NASDAQ:TMDX) from Hold to Buy and announces $148 price target.
Canaccord Genuity analyst William Plovanic maintains TransMedics Group (NASDAQ:TMDX) with a Buy and maintains $142 price tar...
Jefferies analyst Young Li initiates coverage on TransMedics Group (NASDAQ:TMDX) with a Buy rating and announces Price Targe...